Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Lakshminarayana Vogeti
Observed names:
L. Vogeti,
LN Vogeti,
Lakshminarayana, Vogeti,
Vogeti, L.
Institution:
Deciphera Pharmaceuticals (United States)
Observed institutions:
University of Kansas,
Southern Methodist University,
BioCryst Pharmaceuticals (United States),
Deciphera Pharmaceuticals (United States)
OpenAlex ID:
A5045394985
Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants
2019
·
Bryan D. Smith
, Michael D. Kaufman
, et al.
·
Cancer Cell
·
300
Conformational Control Inhibition of the BCR-ABL1 Tyrosine Kinase, Including the Gatekeeper T315I Mutant, by the Switch-Control Inhibitor DCC-2036
2011
·
Wayne W. Chan
, Scott C. Wise
, et al.
·
Cancer Cell
·
227
PDF
Discovery of 1-(3,3-Dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a Pan-RAF Inhibitor with Minimal Paradoxical Activation and Activity against BRAF or RAS Mutant Tumor Cells
2015
·
James R. Henry
, Michael D. Kaufman
, et al.
·
Journal of Medicinal Chemistry
·
96
PDF
Vimseltinib: A Precision CSF1R Therapy for Tenosynovial Giant Cell Tumors and Diseases Promoted by Macrophages
2021
·
Bryan D. Smith
, Michael D. Kaufman
, et al.
·
Molecular Cancer Therapeutics
·
84
Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2
2015
·
Bryan D. Smith
, Michael D. Kaufman
, et al.
·
Molecular Cancer Therapeutics
·
84
Discovery of Vimseltinib (DCC-3014), a Highly Selective CSF1R Switch-Control Kinase Inhibitor, In Clinical Development for the Treatment of Tenosynovial Giant Cell Tumor (TGCT)
2022
·
Timothy M. Caldwell
, Yu Mi Ahn
, et al.
·
Bioorganic & Medicinal Chemistry Letters
·
55
PDF
Design, synthesis, and antiproliferative and CDK2-cyclin a inhibitory activity of novel flavopiridol analogues
2006
·
Yu Mi Ahn
, Lakshminarayana Vogeti
, et al.
·
Bioorganic & Medicinal Chemistry
·
45
Switch control pocket inhibitors of p38-MAP kinase. Durable type II inhibitors that do not require binding into the canonical ATP hinge region
2010
·
Yu Mi Ahn
, Michael Clare
, et al.
·
Bioorganic & Medicinal Chemistry Letters
·
37
Cephalosporin-derived inhibitors of β-Lactamase. Part 4: The C3 substituent
2002
·
John D. Buynak
, Lakshminarayana Vogeti
, et al.
·
Bioorganic & Medicinal Chemistry Letters
·
30
Coupling Reactions of Cephalosporin Sulfones: A Stable 3-Stannylated Cephem
2001
·
John D. Buynak
, Lakshminarayana Vogeti
, et al.
·
Organic Letters
·
28
Discovery of acyl ureas as highly selective small molecule CSF1R kinase inhibitors
2022
·
Timothy M. Caldwell
, Michael D. Kaufman
, et al.
·
Bioorganic & Medicinal Chemistry Letters
·
14
PDF
Abstract B129: Preclinical studies with DCC-3116, an ULK kinase inhibitor designed to inhibit autophagy as a potential strategy to address mutant RAS cancers
2019
·
Bryan D Smith
, Lakshminarayana Vogeti
, et al.
·
Molecular Cancer Therapeutics
·
7
Scaffold hopping via ring opening enables identification of acyclic compounds as new complement Factor D inhibitors
2022
·
Weihe Zhang
, Minwan Wu
, et al.
·
Bioorganic & Medicinal Chemistry
·
6
Abstract 4045: DCC-3084, a RAF dimer inhibitor, broadly inhibits BRAF class I, II, III, BRAF fusions, and RAS-driven solid tumors leading to tumor regression in preclinical models
2023
·
Stacie L. Bulfer
, Bertrand Le Bourdonnec
, et al.
·
Cancer Research
·
4
Discovery and optimization of orally bioavailable and potent plasma Kallikrein inhibitors bearing a quaternary carbon
2022
·
Weihe Zhang
, Satish Vadlakonda
, et al.
·
Bioorganic & Medicinal Chemistry
·
3
Assessing the state of the art in ADMET prediction: Lessons from the OpenADMET-ExpansionRx community blind challenge
2026
·
Maria A. Castellanos
, Hugo MacDermott-Opeskin
, et al.
·
ChemRxiv
·
1
PDF
OpenADMET-ExpansionRx blind challenge data
2026
·
Ainsley, Jon
, Andrew, Good
, et al.
·
Zenodo (CERN European Organization for Nuclear Research)
·
1
The crystal structure of human abl1 kinase domain T315I mutant in complex with DCC-2036
2011
·
W.W. Chan
, S.C. Wise
, et al.
·
Worldwide Protein Data Bank
·
1
Assessing the state of the art in ADMET prediction: Lessons from the OpenADMET-ExpansionRx community blind challenge
2026
·
Maria A. Castellanos
, Hugo MacDermott-Opeskin
, et al.
·
ChemRxiv
PDF
Assessing the state of the art in ADMET prediction: Lessons from the OpenADMET-ExpansionRx community blind challenge
2026
·
Maria A. Castellanos
, Hugo MacDermott-Opeskin
, et al.
·
ChemRxiv
PDF
Abstract 408: Discovery of a first-in-class dual microtubule- and RAF—targeting inhibitor.
2026
·
Joshua W. Large
, Yeni K. Romero
, et al.
·
Cancer Research
Supplementary Figures and Tables from Vimseltinib: A Precision CSF1R Therapy for Tenosynovial Giant Cell Tumors and Diseases Promoted by Macrophages
2025
·
Bryan D. Smith
, Michael D. Kaufman
, et al.
PDF
Data from Vimseltinib: A Precision CSF1R Therapy for Tenosynovial Giant Cell Tumors and Diseases Promoted by Macrophages
2025
·
Bryan D. Smith
, Michael D. Kaufman
, et al.
Data from Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2
2023
·
Bryan D. Smith
, Michael D. Kaufman
, et al.
Supplementary Materials and Methods, Supplementary Tables 1 through 4, and Supplementary Figures 1 through 9 from Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2
2023
·
Bryan D. Smith
, Michael D. Kaufman
, et al.
Show more works
View as search
Works count:
31
Citation count:
1,023
H-index:
11
I10-index:
11
Year
Topic
Type